Market Research Report
Rest of the World Factor VIII Deficiency Treatment Market, by Product Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
|Published by||Coherent Market Insights||Product code||920720|
|Published||Content info||273 Pages
Delivery time: 2-3 business days
|Rest of the World Factor VIII Deficiency Treatment Market, by Product Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027|
|Published: January 3, 2020||Content info: 273 Pages||
Rest of the World Factor VIII Deficiency Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Latin America, Asia Pacific, Middle East & Russia, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.
Hemophilia, a factor VIII deficiency is a genetic disorder that is caused by the absence of factor VIII, which is a clotting protein. Moreover, it is genetically passed down to the offspring and according to the National Hemophilia Foundation, in 2019 about 1/3 cases of factor VIII deficiency occurs due to spontaneous mutation in the gene of the parents. Rising incidences and prevalence of hemophilic disorder are expected to boost growth of the market over the forecast period which leads to product launches in the market by the key players, to fulfill the unmet need of the market. Favorable regulatory scenarios and guidelines for the product launches and treatment are another leading factors that are expected to propel growth of the market over the forecast period.
Furthermore, adoption of inorganic strategies by market players such as collaborations to develop the novel therapies for the treatment is also expected to fuel growth of the factor VIII deficiency treatment market over the forecast period. For instance, in July 2019, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A
Factor VIII deficiency treatment market is expected to witness significant growth over the forecast period, owing to increasing number of hemophilic cases. For instance, according to the World Federation of Hemophilia 2017 statistics, in India, around 18,353 people suffered from hemophilia and 15,218 people were diagnosed with hemophilia A in 2016, out of which around 83.0% had factor VIII deficiency. Moreover, according to the World Federation of Hemophilia reports published in 2017, there were around 10,000 patients with hemophilia A in Brazil. With reference to prior data, World Federation of Hemophilia also reports that in 2017, Brazil had the third largest hemophilia patient population.
Product approvals by the regulatory authorities is expected to drive the growth of factor VIII deficiency treatment market over the forecast period. For instance, in 2019 February, the U.S. Food and Drug Administration approved the biologics license application of Novo Nordisk's long-acting recombinant factor VIII product, N8-GP Turoctocog alfa pegol (Esperoct), for prevention and treatment of individuals with hemophilia A. Moreover, in 2016 March, the U.S. Food and Drug Administration approved Kedrion's, Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for the treatment of factor VIII deficiency.
Major players are also focused on adopting inorganic growth strategies such as acquisitions, which is expected to fuel the market growth over the forecast period. For instance, in 2018, CSL Behring acquired China-based plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. From Humanwell Healthcare Group Co. Ltd. The acquisition has expanded CSL's presence in China's domestic plasma fractionation market. It has also enabled CSL to expand their commercial footprint and contributing their expertise for benefit of patients with rare diseases in China.
"*" marked represents similar segmentation in other categories in the respective section.